David C. Turner - Publications, H-index & Citations

David C. Turner

Genentech

46H指数

281论文数

7.3K被引数

收录论文 39

发表时间

Pharmaceutical Industry Perspectives on Exposure-Response Confounding in Large Molecule Therapeutics: Results From an IQ Consortium Survey 制药行业对大分子治疗药物中暴露-反应混杂因素的观点：IQ联盟调查结果

CPT-Pharmacometrics & Systems Pharmacology

IF3

2026-09-16

OAAI

Engie Salama; Manisha Lamba; Sihem Ait-Oudhia; Ellen Wang; Dorothee Semiond; Zhang Li; Tao Long; Satyendra Suryawanshi; Leticia Arrington; Wei Gao; Xiaowen Guan; Hugh Giovinazzo; Dale Miles; David C. Turner

Follow-Up Bias in Tumor Dynamic Modeling: A Comparison of Classical and Neural-ODE Approaches 肿瘤动力学建模中的随访偏倚：经典方法与神经ODE方法的比较

cpt: pharmacometrics & systems pharmacology

IF0

2026-04-01

OAAI

David C. Turner; Mark Laurie; Shuhui Li; Huy X. Ngo; Chunze Li; Jin Y. Jin; James Lu; Logan Brooks

The comprehensive update of the Entrustable Professional Activities for General Pediatrics 普通儿科可信赖专业活动的全面更新

Academic Pediatrics

IF2.8

2025-11-22

PREAI

Laura Chiel; Meghan O'Connor; Joanna Lewis; Andrew Dwyer; Brenda Nuncio; Cathy Koenig; Patricia Poitevien; Ariel Winn; David Turner

Tocilizumab Dosing for Management of T Cell-Engaging Bispecific Antibody-Related CRS in Patients With R/R B-Cell NHL 托珠单抗剂量用于管理R/R B细胞NHL患者T细胞结合型双特异性抗体相关细胞因子释放综合征（CRS）

Clinical Pharmacology & Therapeutics

IF5.5

2025-06-27

PREAI

Candice Jamois; David C. Turner; Leonid Gibiansky; Feifei Li; Jean-Francois Menuet; Leonardo Roque Pereira; Linda Lundberg; Elena Guerini; David J. Carlile; James Relf; Michael C. Wei; Antonia Kwan; Nicolas Frey; Susan Grange

Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma 中国复发或难治性滤泡性淋巴瘤患者中mosunetuzumab药代动力学和药效学的种族敏感性评估

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2025-04-25

OAAI

Li, Junyi; Liao, Michael Z.; Wilkins, Justin; Penuel, Elicia; Wang, Bei; Vadhavkar, Shweta; Peng, Kun; Cao, Junning; Li, Zhiming; Zhang, Ye; Li, Wenjin; Li, Donghang; Zhou, Mingzhu; Wei, Michael C.; Kwan, Antonia; Zhao, Rong; Li, Chunze; Li, Chi-Chung; Turner, David C.

Cytokine Release Syndrome: Trends with T Cell Engaging Bispecifics from a Systematic Review of Licensing Applications 细胞因子释放综合征：基于对T细胞结合型双特异性抗体许可申请的系统综述中的趋势

BLOOD

IF23.1

2024-11-05

PREAI

Radtke, Kendra; Bender, Brendan C.; Li, Zao; Turner, David C.; Roy, Sumi; Belousov, Anton; Li, Chi-Chung

Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-05-29

OAAI

Bender, Brendan; Li, Chi-Chung; Marchand, Mathilde; Turner, David C.; Li, Feifei; Vadhavkar, Shweta; Wang, Bei; Deng, Rong; Lu, James; Jin, Jin; Li, Chunze; Yin, Shen; Wei, Michael; Chanu, Pascal

Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-01-31

OAAI

Turner, David C.; Wada, Russ; Zhou, Helen; Wang, Xiaowei; de Greef, Rik; Valiathan, Chandni; Zhang, Lindsey; Zhang, Nancy; Kuchimanchi, Mita; Chen, Tai-Tsang; Ballas, Marc; Visser, Sandra A. G.

Pharmacokinetics of biologics in gastric cancer

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2023-01-18

OAAI

Li, Junyi; Turner, David C.; Li, Feifei; Chen, Xi; Liao, Michael Z.; Li, Chunze

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma

NATURE COMMUNICATIONS

IF15.7

2022-09-08

OAAI

Gyurdieva, Alexandra; Zajic, Stefan; Chang, Ya-Fang; Houseman, E. Andres; Zhong, Shan; Kim, Jaegil; Nathenson, Michael; Faitg, Thomas; Woessner, Mary; Turner, David C.; Hasan, Aisha N.; Glod, John; Kaplan, Rosandra N.; D'Angelo, Sandra P.; Araujo, Dejka M.; Chow, Warren A.; Druta, Mihaela; Demetri, George D.; Van Tine, Brian A.; Grupp, Stephan A.; Fine, Gregg D.; Eleftheriadou, Ioanna

The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis

ANNALS OF ONCOLOGY

IF65.4

2020-09-01

OAAI

Wang, X.; Ballas, M.; Chen, H.; Bell, K. F.; Slowley, A.; Ellis, C.; Baccan, C.; Turner, D. C.; Zhou, H.

PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine plus nab-paclitaxel or FOLFIRINOX chemotherapy

ANNALS OF ONCOLOGY

IF65.4

2020-07-01

OAAI

Ross, P.; Hendlisz, A.; Ajithkumar, T.; Iwuji, C.; Harris, M.; Croagh, D.; Aghmesheh, M.; Nagrial, A.; Nguyen, N.; Nikfarjam, M.; Wilson, N.; Kenny, D.; Turner, D.; Wasan, H.

Naive indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine plus nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer

ANNALS OF ONCOLOGY

IF65.4

2020-07-01

OAAI

Allerdice, S.; Wilson, N.; Turner, D.; McCloud, P.; Kenny, D.; Cowley, A.; Taylor, C.

Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study

ANNALS OF ONCOLOGY

IF65.4

2020-03-01

OAAI

Angevin, E.; Groenland, S.; Bauer, T.; Rischin, D.; Gardeazabal, I.; Moreno, V.; Trigo, J. M.; Chisamore, M.; Shaik, J.; Rigat, F.; Ellis, C.; Chen, H.; Gagnon, R.; Scherer, S. J.; Turner, D.; Yadavilli, S.; Ballas, M.; Hoos, A.; Maio, M.

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study MEK抑制剂司美替尼 (AZD6244) 在复发性或难治性低级别神经胶质瘤患儿中的I期试验: 小儿脑肿瘤联盟 (PBTC) 研究

NEURO-ONCOLOGY

IF13.4

2017-02-28

225

OAAI

Banerjee, Anuradha; Jakacki, Regina I.; Onar-Thomas, Arzu; Wu, Shengjie; Nicolaides, Theodore; Poussaint, Tina Young; Fangusaro, Jason; Phillips, Joanna; Perry, Arie; Turner, David; Prados, Michael; Packer, Roger J.; Qaddoumi, Ibrahim; Gururangan, Sridharan; Pollack, Ian F.; Goldman, Stewart; Doyle, Lawrence A.; Stewart, Clinton F.; Boyett, James M.; Kun, Larry E.; Fouladi, Maryam

Exposure-response analysis of pembrolizumab in patients with advanced melanoma and non-small cell lung cancer enrolled in KEYNOTE-001,-002 and-006

CANCER RESEARCH

IF16.6

2016-07-15

PREAI

Chatterjee, Manash S.; Turner, David C.; Ahamadi, Malidi; de Greef, Rik; Freshwater, Tomoko; Mayawala, Kapil; Dong, David; Stone, Julie; de Alwis, Dinesh; Kondic, Anna

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer 派姆单抗治疗晚期非小细胞肺癌的系统评价

ANNALS OF ONCOLOGY

IF65.4

2016-07-01

135

OAAI

Chatterjee, M.; Turner, D. C.; Felip, E.; Lena, H.; Cappuzzo, F.; Horn, L.; Garon, E. B.; Hui, R.; Arkenau, H. -T.; Gubens, M. A.; Hellmann, M. D.; Dong, D.; Li, C.; Mayawala, K.; Freshwater, T.; Ahamadi, M.; Stone, J.; Lubiniecki, G. M.; Zhang, J.; Im, E.; De Alwis, D. P.; Kondic, A. G.; Flotten, O.

Phase I study of 5-fluorouracil in children and young adults with recurrent ependymoma 5-氟尿嘧啶在儿童和年轻人复发性室管膜瘤中的I期研究

NEURO-ONCOLOGY

IF13.4

2015-11-04

OAAI

Wright, Karen D.; Daryani, Vinay M.; Turner, David C.; Onar-Thomas, Arzu; Boulos, Nidal; Orr, Brent A.; Gilbertson, Richard J.; Stewart, Clinton F.; Gajjar, Amar

Relationship between pembrolizumab exposure and efficacy/safety in 1016 patients (pts) with advanced or metastatic melanoma

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-01

PREAI

Kang, S. P.; Chatterjee, M.; Ahamadi, M.; De Alwis, D.; De Greef, R.; Elassaiss-Schaap, J.; Freshwater, T.; Mayawala, K.; Stone, J.; Ebbinghaus, S.; Turner, D.; Kondic, A.

Age dependent disposition of cyclophosphamide (CTX) and metabolites in infants ≤ 1 year old with brain tumors

CANCER RESEARCH

IF16.6

2015-08-01

PREAI

Daryani, Vinay M.; Owens, Thandranese S.; Harstead, K. Elaine; Patel, Yogesh T.; Turner, David C.; Throm, Stacy L.; Panetta, John C.; Gajjar, Amar; Stewart, Clinton F.

研究方向